Targets › DYRK2
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2026.
Serine/threonine-protein kinase involved in the regulation of the mitotic cell cycle, cell proliferation, apoptosis, organization of the cytoskeleton and neurite outgrowth. Phosphorylates CRMP2/DPYSL2, CRMP4/DPYSL3, DCX, EIF2B5, EIF4EBP1, GLI2, GLI3, GYS1, JUN, MDM2, MYC, NFATC1, p53/TP53, TAU/MAPT and KATNA1. (UniProt, Q92630)
Open in Phaseline: the race on DYRK2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Tasly Pharmaceuticals | TSL2109 CDK4/6-DYRK2 dual-target inhibitor | CDK4, CDK6, DYRK2 | Phase 1 | Metastatic Castration-Resistant Prostate Cancer Patients | Dec 2026 |
Metastatic Castration-Resistant Prostate Cancer Patients (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.